HIF-1α and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides

Current Cancer Drug Targets

Volumn 9, Issue 7, 2009, Pages 881-887

  Lin, J ^a   Denmeade, S ^c   Carducci, M A ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NONE

Author keywords

Calcium; Cardiac glycosides; Digoxin; HIF 1 ; Prostate cancer

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANDROGEN RECEPTOR; ANVIRZEL; CALCIUM ION; CARDIAC GLYCOSIDE; CP 4071; DIGITOXIN; DIGOXIN; ERLOTINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAPATINIB; NERIUM OLEANDER EXTRACT; OUABAIN; PROSCILLARIDIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPOXIA; LUNG NON SMALL CELL CANCER; NAUSEA; NONHUMAN; PROSTATE CANCER; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VOMITING; ANOXIA; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

ANOXIA; ANTINEOPLASTIC AGENTS; CALCIUM SIGNALING; CARDIAC GLYCOSIDES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; RECEPTOR CROSS-TALK; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 72849153162     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909789760249     Document Type: Review

References (52)

1. Berges, R. R.; Vukanovic, J.; Epstein, J. I.; CarMichel, M.; Cisek, L.; Johnson, D. E.; Veltri, R. W.; Walsh, P. C.; Isaacs, J. T. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. 1995, 1, 473-480.
2. Heath, E. I.; Carducci, M. A.; New targets in the management of prostate cancer. Hematol. Oncol. Clin. North Am. 2006, 20, 985-999, xi.
3. Wang, G. L.; Jiang, B. H.; Rue, E. A.; Semenza, G. L.; Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 1995, 92, 5510-5514.
4. Harris, A. L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2, 38-47. (Pubitemid 37328806)
5. Blancher, C.; Harris, A. L. The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastasis Rev. 1998, 17, 187-194.
6. Semenza, G. L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 2007, 12, 853-859.
7. Powis, G.; Kirkpatrick, L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol. Cancer Ther. 2004, 3, 647-654. (Pubitemid 39193744)
8. Butterworth, K. T.; McCarthy, H. O.; Devlin, A.; Ming, L.; Robson, T.; McKeown, S. R.; Worthington, J. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int. J. Cancer 2008, 123, 760-768. (Pubitemid 352032400)
9. Movsas, B.; Chapman, J. D.; Horwitz, E. M.; Pinover, W. H.; Greenberg, R. E.; Hanlon, A. L.; Iyer, R.; Hanks, G. E. Hypoxic regions exist in human prostate carcinoma. Urology 1999, 53, 11-18. (Pubitemid 29016607)
10. Zhong, H.; De Marzo, A. M.; Laughner, E.; Lim, M.; Hilton, D. A.; Zagzag, D.; Buechler, P.; Isaacs, W. B.; Semenza, G, L,; Simons, J. W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59, 5830-5835.
11. Zhong, H.; Agani, F.; Baccala, A. A.; Laughner, E.; Rioseco-Camacho, N.; Isaacs, W. B.; Simons, J. W.; Semenza, G. L. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res. 1998, 58, 5280-5284. (Pubitemid 28551099)
12. Zhong, H.; Chiles, K.; Feldser, D.; Laughner, E.; Hanrahan, C.; Georgescu, M. M.; Simons, J. W.; Semenza, G. L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60, 1541-1545.
13. Lin, J.; Adam, R. M.; Santiestevan, E.; Freeman, M. R. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res. 1999, 59, 2891-2897.
14. Mabjeesh, N. J.; Willard, M. T.; Frederickson, C. E.; Zhong, H.; Simons, J. W. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/ phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin. Cancer Res. 2003, 9, 2416-2425.
15. Thomas, R.; Kim, M. H. HIF-1 alpha: a key survival factor for serum-deprived prostate cancer cells. Prostate 2008, 68, 1405-1415.
16. Horii, K.; Suzuki, Y.; Kondo, Y.; Akimoto, M.; Nishimura, T.; Yamabe, Y.; Sakaue, M.; Sano, T.; Kitagawa, T.; Himeno, S.; et al. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol. Cancer Res. 2007, 5, 383-391.
17. Williams, S. A.; Singh, P.; Isaacs, J. T.; Denmeade, S. R. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2007, 67, 312-329.
18. Boddy, J. L.; Fox, S. B.; Han, C.; Campo, L.; Turley, H.; Kanga, S.; Malone, P. R.; Harris, A. L. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin. Cancer Res. 2005, 11, 7658-7663.
19. Park, S. Y.; Kim, Y. J.; Gao, A. C.; Mohler, J. L.; Onate, S. A.; Hidalgo, A. A.; Ip, C.; Park, E. M.; Yoon, S. Y.; Park, Y. M. Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res. 2006, 66, 5121-5129. (Pubitemid 43844934)
20. Stewart, R. J.; Panigrahy, D.; Flynn, E.; Folkman, J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J. Urol. 2001, 165, 688-693. (Pubitemid 32060501)
21. Cheng, L.; Zhang, S.; Sweeney, C. J.; Kao, C.; Gardner, T. A.; Eble, J. N. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Res. 2004, 24, 2135-2140.
22. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721-732.
23. Kimbro, K. S.; Simons, J. W. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr. Relat. Cancer 2006, 13, 739-749. (Pubitemid 44763255)
24. Kyprianou, N.; English, H. F.; Isaacs, J. T. Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castrationinduced prostatic cell death. Prostate 1988, 13, 103-117.
25. Martikainen, P.; Isaacs, J. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 1990, 17, 175-187.
26. Zhu, N.; Wang, Z. Calreticulin expression is associated with androgen regulation of the sensitivity to calcium ionophore-induced apoptosis in LNCaP prostate cancer cells. Cancer Res. 1999, 59, 1896-1902. (Pubitemid 29186163)
27. Marin, M. C.; Fernandez, A.; Bick, R. J.; Brisbay, S.; Buja, L. M.; Snuggs, M.; McConkey, D. J.; von Eschenbach, A. C.; Keating, M. J.; McDonnell, T. J. Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+. Oncogene 1996, 12, 2259-2266. (Pubitemid 26192705)
28. Humez, S.; Legrand, G.; Vanden-Abeele, F.; Monet, M.; Marchetti, P.; Lepage, G.; Crepin, A.; Dewailly, E.; Wuytack, F.; Prevarskaya, N. Role of endoplasmic reticulum calcium content in prostate cancer cell growth regulation by IGF and TNFalpha. J. Cell Physiol. 2004, 201, 201-213. (Pubitemid 39305098)
29. Schwarze, S. R.; Lin, E. W.; Christian, P. A.; Gayheart, D. T.; Kyprianou, N. Intracellular death platform steps-in: targeting prostate tumors via endoplasmic reticulum (ER) apoptosis. Prostate 2008, 68, 1615-1623.
30. Denmeade, S. R.; Isaacs, J. T. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biol. Ther. 2005, 4, 14-22.
31. Zhang, H.; Qian, D. Z.; Tan, Y. S.; Lee, K.; Gao, P.; Ren, Y. R.; Rey, S.; Hammers, H.; Chang, D.; Pili, R.; et al. Inaugural Article: Digoxin and other cardiac glycosides inhibit HIF-1{alpha} synthesis and block tumor growth. Proc. Natl. Acad. Sci. USA 2008.
32. Florkiewicz, R. Z.; Anchin, J.; Baird, A. The inhibition of fibroblast growth factor-2 export by cardenolides implies a novel function for the catalytic subunit of Na+,K+-ATPase. J. Biol. Chem. 1998, 273, 544-551. (Pubitemid 28042243)
33. Smith, J. A.; Madden, T.; Vijjeswarapu, M.; Newman, R. A. Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem. Pharmacol. 2001, 62, 469-472.
34. Svensson, A.; Azarbayjani, F.; Backman, U.; Matsumoto, T.; Christofferson, R. Digoxin inhibits neuroblastoma tumor growth in mice. Anticancer Res. 2005, 25, 207-212. (Pubitemid 40470112)
35. Hauptman, P. J.; Kelly, R. A. Digitalis. Circulation 1999, 99, 1265-1270.
36. Stenkvist, B. Is digitalis a therapy for breast carcinoma? Oncol. Rep. 1999, 6, 493-496.
37. Stenkvist, B.; Pengtsson, E.; Dahlqvist, B.; Eriksson, O.; Jarkrans, T.; Nordin, B. Cardiac glycosides and breast cancer, revisited. N. Engl. J. Med. 1982, 306, 484.
38. Winnicka, K.; Bielawski, K.; Bielawska, A.; Miltyk, W. Apoptosis-mediated cytotoxicity of ouabain, digoxin and proscillaridin A in the estrogen independent MDA-MB-231 breast cancer cells. Arch. Pharm. Res. 2007, 30, 1216-1224.
39. Bielawski, K.; Winnicka, K.; Bielawska, A. Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol. Pharm. Bull. 2006, 29, 1493-1497.
40. Kometiani, P.; Liu, L.; Askari, A. Digitalis-induced signaling by Na+/K+-ATPase in human breast cancer cells. Mol. Pharmacol. 2005, 67, 929-936.
41. Yeh, J. Y.; Huang ,W. J.; Kan, S. F.; Wang, P. S. Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells. J. Urol. 2001, 166, 1937-1942.
42. McConkey, D. J.; Lin, Y.; Nutt, L. K.; Ozel, H. Z.; Newman, R. A. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res. 2000, 60, 3807-3812.
43. Hornestam, B.; Jerling, M.; Karlsson, M. O.; Held, P. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. Eur. J. Clin. Pharmacol. 2003, 58, 747-755. (Pubitemid 36399231)
44. Katzung, B.; Parmley, W. W. Cardiac glycosides and other drugs used in congestive heart failure. Basic and Clinical Pharmacology; 8th ed (Katzung BG ed), McGraw-Hill Book Company: New York, 2001, pp. 200-218.
45. Lin, H.; Juang, J. L.; Wang, P. S. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. J. Biol. Chem. 2004, 279, 29302-29307. (Pubitemid 38915807)
46. Newman, R. A.; Yang, P.; Pawlus, A. D.; Block, K. I. Cardiac glycosides as novel cancer therapeutic agents. Mol. Interv. 2008, 8, 36-49.
47. Isaacs, J. T. The biology of hormone refractory prostate cancer. Why does it develop? Urol. Clin. North Am. 1999, 26, 263-273. (Pubitemid 29228223)
48. Mekhail, T.; Kaur, H.; Ganapathi, R.; Budd, G. T.; Elson, P.; Bukowski, R. M. Phase 1 trial of Anvirzel in patients with refractory solid tumors. Invest. New Drugs 2006, 24, 423-427. (Pubitemid 43876078)
49. Giatromanolaki, A.; Koukourakis, M. I.; Simopoulos, C.; Polychronidis, A.; Gatter, K. C.; Harris, A. L.; Sivridis, E. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin. Cancer Res. 2004, 10, 7972-7977.
50. Lim, J. H.; Lee, E. S.; You, H. J.; Lee, J. W.; Park, J. W.; Chun, Y. S. Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 2004, 23, 9427-9431.
51. Giatromanolaki, A.; Koukourakis, M. I.; Sivridis, E.; Turley, H.; Talks, K.; Pezzella, F.; Gatter, K. C.; Harris, A. L. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 2001, 85, 881-890.
52. Shintani, K.; Matsumine, A.; Kusuzaki, K.; Matsubara, T.; Satonaka, H.; Wakabayashi, T.; Hoki, Y.; Uchida, A. Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch. 2006, 449, 673-681. (Pubitemid 44832639)